03 January 2020
Visiongain has published a New pharma report of Top 25 Anaesthesia Drugs Manufacturers 2020: Novartis, Mylan, Teva, Merck and Other Companies.
The Global Anaesthesia Drugs Market is estimated to grow at a CAGR of 3.9% from 2019 to 2024, dominated by the local anaesthesia submarket. The global anaesthesia drugs market is projected to grow at lucrative rate during the forecast period owing to a rising number of surgical procedures globally, developing healthcare infrastructure in emerging economies, and growing number of geriatric population.
This report profiled the selected companies: Abbott Laboratories, AbbVie, Aspen Pharmacare, AstraZeneca, B. Braun Melsungen AG, Baxter International, Boehringer Ingelheim, Eisai, Endo International and other companies.
The lead analyst commented that "Advancements in the anaesthesia drug delivery methods, such as jet injection, inhalation and computer-controlled anaesthesia delivery systems will further encourage the general anaesthesia drugs industry. Over the years, the emergence of new medications, technology, and knowledge has revolutionized perioperative medicine, and as a consequence, interest in how these changes affect anaesthetic care and practice has emerged."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.